Search
Now showing items 31-40 of 88
Intensified carboplatin regimen with GM-CSF support in non-small cell lung cancer (NSCLC). A Hellenic Co-operative Oncology Group study (HeCOG)
(1997)
This is a continuation of a HeCOG previous trial utilizing carboplatin and vindesine in conventional doses as a non-toxic regimen provided easily on an outpatient basis in NSCLC. In the present study we investigated whether ...
Carcinoma of unknown primary: Natural history and treatment. Analysis of 30 cases and review of the literature
(1990)
In this study, the natural history and therapeutic management of 30 patients with carcinoma of unknown primary (CUP syndrome) is presented. Despite detailed laboratory investigations, the primary occult tumor was not ...
Evaluation of six tumor markers in patients with carcinoma of unknown primary
(1994)
We have retrospectively evaluated six serum tumor markers in 85 patients with carcinoma of unknown primary. The serum levels of carcinoembryonic antigen (CEA), CA 19‐9, CA 15‐3, CA 125, β‐chorionic gonadotropin (β‐HCG) and ...
Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: Preliminary results of a Hellenic Cooperative Ontology Group study
(1997)
Ninety previously untreated patients with advanced epithelial ovarian cancer (International Federation of Gynecology and Obstetrics stages IIC, III, and IV) were randomized, after initial cytoreductive surgery, to receive ...
Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study
(1997)
Background: Based on the high activity of single-agent paclitaxel and the superior one-year survival rates of patients with non-small-cell lung cancer (NSCLC) treated with carboplatin, a phase II trial was initiated using ...
Serum‐soluble interleukin‐2 receptors in B‐cell lymphoproliferative malignancies
(1992)
The levels of soluble interleukin‐2 receptors (sIL‐2R) were determined in the serum of 53 patients with B‐cell lymphoproliferative malignancies, including 31 patients with non‐Hodgkin lymphomas (NHL), 16 with chronic ...
A successfully treated case of multicentric angiofollicular hyperplasia with oral chemotherapy (Castleman's disease)
(1990)
A case of angiofollicular lymph node hyperplasia of plasma cell type in a 60‐year‐old woman is reported. The patient presented with lymphadenopathy, splenomegaly, and fever. She responded dramatically to chlorambucil and ...
Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: A study of the Hellenic Cooperative Oncology Group
(1999)
This trial was conducted by the Hellenic Cooperative Oncology Group to improve the responses and survival in small cell lung cancer with a good prognosis, using a weekly intensive chemotherapy with alternated non-cross- ...
p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: A ten-year follow-up study
(1998)
The aim of this study was the evaluation of p53/MDM-2 protein overexpression in different subtypes of human sarcomas, and their correlation with proliferative activity and patient outcome. We selected 40 cases of human ...
Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: Biological and clinical implications. A Hellenic co-operative oncology group study
(1998)
We have previously shown that metastatic carcinomas of unknown primary site overexpress several tumor markers as well as the products of the oncogenes c-myc, ras and c-erbB2. We analysed the tissue expression of the protein ...